Invasive pulmonary aspergillosis (IPA) continues to rise in concert with increasing numbers of immune suppression techniques to treat other medical conditions and transplantation. Despite these advances, morbidity and mortality remain unacceptably high. One strategy utilized to optimize outcomes is antifungal pharmacodynamic (PD) examination. We explored the pharmacodynamics of a new triazole in development, 
INTRODUCTION
Invasive pulmonary aspergillosis (IPA) is a common cause of morbidity and mortality in immunocompromised patients (1-7). The development of Aspergillus active triazoles was a major step forward in therapy; however, morbidity and mortality remain unacceptably high. Additionally, the emergence of Cyp51 mutant isolates that confer decreased susceptibility to triazoles is a threat to the efficacy of this drug class (8-13).
Therefore, development of novel compounds and examination of the pharmacodynamic relationships of drug exposure, MIC, and outcome are necessary for the optimal utilization of these drugs.
Pharmacodynamic studies integrate the pharmacokinetic properties of a drug, in vitro potency (MIC), and treatment efficacy. Common goals of these PD studies are to maximize clinical outcome through dosing optimization and assist in susceptibility breakpoint determination. These investigations have been integral in the optimal use of antibiotics for bacterial infections and antifungal agents for mucosal and invasive candidiasis (14-18). However, only recently have pharmacodynamic investigations been utilized for filamentous fungal infections such as IPA (19-23).
In vitro susceptibility testing. All isolates were tested by broth microdilution in accordance with CLSI document M38-A2 (31) . MICs were performed in duplicate three times. The median value is reported in Table 1 with 5 ml of normal saline and 0.05% Tween-20. Gentle agitation was applied to release the conidia. The conidial suspension was collected and quantified by hemocytometer (Bright-Line, Hausser Scientific, Horsham, PA). The suspension was diluted to a final concentration of 1.2 x 10 7 conidia/ml. Viability was confirmed by plating the suspension and performing CFU counts.
An aspiration pneumonia model was utilized as previously described (20).
Briefly, mice were anesthetized with a combination of ketamine and xylazine. Fifty microliters of the 1-2 x 10 7 conidia/ml suspension was pipetted into the anterior nares with the mice held upright to allow for aspiration into the lungs. As previously shown and confirmed in the current study (data not shown) this results in invasive aspergillosis in over 90% of animals and 100% mortality in untreated infected mice prior to the study endpoint (20). Drug treatment commenced two hours after initiation of infection.
Lung processing and organism quantitation. Processing and quantitation of
Aspergillus burden in the lungs of mice was performed as previously described (35, 36) .
Briefly, at the time of sacrifice for moribund animals or at the end of therapy (7 days), lungs were aseptically harvested and placed in a 2-ounce sterile polyethylene Whirl-Pak bag (Nasco, Fort Atkinson, WI) containing 2 ml of sterile 0.85% NaCl. The lungs were manually homogenized using direct pressure (37) to produce a primary homogenate.
One ml of this primary homogenate was then placed in a sterile bead beating tube Quantitative PCR (qPCR) plates were prepared on the day of assay. Standard quantities of conidia were prepared by hemacytometer counts and were utilized to generate standard curves. The results are reported as conidial equivalents (C.E.) per ml of lung homogenate. Samples were assayed in triplicate using a Bio-Rad CFX96 Realtime system (Hercules, CA). A single copy gene, Fks1, was chosen for quantitation (38) . Data analysis. The qPCR data was modeled according to a Hill-type dose response equation: log 10 D = log 10 (E/E max -E)/N + log 10 ED 50 , where D is the drug dose, E is the growth over the study period as measured by qPCR and represented as C.E./ml lung homogenate in untreated control mice, E max is the maximal drug effect, N is the slope of the dose-response curve, and ED 50 is the dose needed to achieve 50% maximal effect.
The AUC/MIC for total and free drug was determined for each isolate. The coefficient of determination (R 2 Dose-response curves. A dose-response relationship was observed for each isolate with higher doses of isavuconazole achieving a larger microbiologic effect (Figure 2) .
However, higher doses were necessary to achieve similar microbiologic effect against isolates with elevated isavuconazole MICs. A net static outcome and cidal activity was achieved for all wild type isolates as well as 2 of 6 Cyp51 mutants. Maximal effect against wild type isolates was approximately a 2 log 10 reduction in organism burden compared to that in the lungs at the start of therapy and nearly a 4 log 10 compared to untreated controls at the end of therapy.
PD index and target magnitude.
The doses needed to produce net growth suppression (i.e. static dose) and to produce 1 log 10 kill are shown in Total and free drug AUC/MIC PD targets are shown in Table 2 . The free drug AUC/MIC associated with net stasis for the Cyp51 wild type group ranged from 4.15 -11.1; whereas for the two mutant isolates for which this endpoint was slightly lower at 3.61 -3.67. The difference between the two groups was not statistically significant (p = Cyp51 G434C a Defined as the growth, measured in log10 C.E./ml lung homogenate, of the isolate in untreated animals until time of death or sacrifice.
